Skip to Main Content

Advertisement intended for health care professionals

Close

ASH Clinical News
ASH News Daily
ASH-SAP
Blood Journals
Hematology
The Hematologist
International
ASH
- ASH Home
- Research
- Education
- Advocacy
- Meetings
- Publications
- ASH Store

header search

search input Search input auto suggest

filter your search

Search

Menu

Issues
- Current Issue
- All Issues
First edition
Abstracts
Collections
Author Center
About

Skip Nav Destination

Issue Archive

Select Decade

Select Year

Issue

Volume 133, Issue 26

June 27 2019

In this Issue

BLOOD COMMENTARIES
CLINICAL TRIALS AND OBSERVATIONS
GENE THERAPY
LYMPHOID NEOPLASIA
TRANSPLANTATION
LETTERS TO BLOOD
BLOOD WORK

Table of Contents

BLOOD COMMENTARIES

GENE THERAPY

Gene editing in hemophilia: a “CRISPR” choice?

Steven W. Pipe,Sundar R. Selvaraj

View Articletitled, Gene editing in hemophilia: a “CRISPR” choice?

Lymphoid Neoplasia

Deciphering hydroa vacciniforme

Leticia Quintanilla-Martinez,Falko Fend

View Articletitled, Deciphering hydroa vacciniforme

Lymphoid Neoplasia

A one-two punch with VO KOs CLL

Steven Coutre

View Articletitled, A one-two punch with VO KOs CLL

TRANSPLANTATION

Nuke less for less cancer

Mohamad Mohty

View Articletitled, Nuke less for less cancer

CLINICAL TRIALS AND OBSERVATIONS

Proteomic evidence of specific IGKV1-8 association with cystic lung light chain deposition disease
Clinical Trials & Observations Brief Report

Mylène Camus,Sandrine Hirschi,Grégoire Prevot,Marie-Pierre Chenard,Hervé Mal,Marc Stern,Martine Reynaud-Gaubert,Julia Gilhodes,Odile Burlet-Schiltz,Pierre Brousset,Magali Colombat

View Articletitled, Proteomic evidence of specific IGKV1-8 association with cystic lung light chain deposition disease

Supplemental data

GENE THERAPY

CRISPR/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX–knockout mice

Lili Wang,Yang Yang,Camilo Ayala Breton,John White,Jia Zhang,Yan Che,Alexei Saveliev,Deirdre McMenamin,Zhenning He,Caitlin Latshaw,Mingyao Li,James M. Wilson

View Articletitled, CRISPR/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX–knockout mice

Supplemental data

LYMPHOID NEOPLASIA

Hydroa vacciniforme–like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites
Clinical Trials & Observations

Jeffrey I. Cohen,Irini Manoli,Kennichi Dowdell,Tammy A. Krogmann,Deborah Tamura,Pierce Radecki,Wei Bu,Siu-Ping Turk,Kelly Liepshutz,Ronald L. Hornung,Hiva Fassihi,Robert P. Sarkany,Lori L. Bonnycastle,Peter S. Chines,Amy J. Swift,Timothy G. Myers,Melissa A. Levoska,John J. DiGiovanna,Francis S. Collins,Kenneth H. Kraemer,Stefania Pittaluga,Elaine S. Jaffe

There is a Blood Commentary on this article in this issue.

View Articletitled, Hydroa vacciniforme–like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites

Supplemental data

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
Clinical Trials & Observations

Ian W. Flinn,John G. Gribben,Martin J. S. Dyer,William Wierda,Michael B. Maris,Richard R. Furman,Peter Hillmen,Kerry A. Rogers,Swaminathan Padmanabhan Iyer,Anne Quillet-Mary,Loic Ysebaert,Harriet S. Walter,Maria Verdugo,Christian Klein,Huang Huang,Yanwen Jiang,Gerard Lozanski,Daniela Soriano Pignataro,Kathryn Humphrey,Mehrdad Mobasher,Thomas J. Kipps

There is a Blood Commentary on this article in this issue.

View Articletitled, Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Supplemental data

Recurrent MSC^E116K mutations in ALK-negative anaplastic large cell lymphoma

Rebecca A. Luchtel,Michael T. Zimmermann,Guangzhen Hu,Surendra Dasari,Manli Jiang,Naoki Oishi,Hailey K. Jacobs,Yu Zeng,Tanya Hundal,Karen L. Rech,Rhett P. Ketterling,Jeong-Heon Lee,Bruce W. Eckloff,Huihuang Yan,Krutika S. Gaonkar,Shulan Tian,Zhenqing Ye,Marshall E. Kadin,Jagmohan Sidhu,Liuyan Jiang,Jesse Voss,Brian K. Link,Sergei I. Syrbu,Fabio Facchetti,N. Nora Bennani,Susan L. Slager,Tamas Ordog,Jean-Pierre Kocher,James R. Cerhan,Stephen M. Ansell,Andrew L. Feldman

View Articletitled, Recurrent <em>MSC</em><sup>E116K</sup> mutations in ALK-negative anaplastic large cell lymphoma

Supplemental data

TRANSPLANTATION

Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation
Clinical Trials & Observations

K. Scott Baker,Wendy M. Leisenring,Pamela J. Goodman,Ralph P. Ermoian,Mary E. Flowers,G. Schoch,Rainer Storb,Brenda M. Sandmaier,H. Joachim Deeg

View Articletitled, Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation

Supplemental data

LETTERS TO BLOOD

Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection
Clinical Trials & Observations

Paolo Strati,Loretta J. Nastoupil,Luis E. Fayad,Felipe Samaniego,Sherry Adkins,Sattva S. Neelapu

View Articletitled, Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation

Giada Rotunno,Carmela Mannarelli,Giada Brogi,Annalisa Pacilli,Francesca Gesullo,Francesco Mannelli,Sara Fiaccabrino,Benedetta Sordi,Chiara Paoli,Ilaria Marone,Elisa Rumi,Rossella Manfredini,Giovanni Barosi,Mario Cazzola,Alessandro M. Vannucchi,Paola Guglielmelli

View Articletitled, Spectrum of <em>ASXL1</em> mutations in primary myelofibrosis: prognostic impact of the <em>ASXL1</em> p.G646Wfs*12 mutation

Supplemental data

BLOOD WORK

Striking emperipolesis in megakaryocytes of gray platelet syndrome

Eric McGinnis,Kate M. Chipperfield

View Articletitled, Striking emperipolesis in megakaryocytes of gray platelet syndrome

Cover Image

Cover Image

Eosinophilic extracellular amorphous Congo red–negative deposits admixed with some plasma cells without atypia are the histological hallmark of pulmonary light chain deposition disease (LCDD), an entity clinically and molecularly distinct from systemic LCDD. See the article by Camus et al on page 2741.
Front Matter
Table of Contents
Back Matter
Editorial Board

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Non-V600E BRAF mutations and treatment for Hairy Cell Leukemia

How I Treat AML relapse after allogeneic HCT

Menin inhibitors in the treatment of acute myeloid leukemia

Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study

How I treat quantitative fibrinogen disorders

Advertisement intended for health care professionals

Advertisement intended for health care professionals

Current Issue
First edition
All Issues

Collections
Abstracts
Authors

Submit to Blood
About Blood
Subscriptions

Public Access
Permissions
Alerts

Contact Us
Newsroom
Blood Classifieds

Advertising in Blood
Terms and Conditions
Twitter

American Society of Hematology
2021 L Street NW, Suite 900
Washington, DC 20036
TEL +1 202-776-0544
FAX +1 202-776-0545

ASH Publications

Blood
Blood Advances
Blood Global Hematology
Blood Neoplasia
Blood Vessels, Thrombosis & Hemostasis
Hematology, ASH Education Program
ASH Clinical News
ASH-SAP
The Hematologist

American Society of Hematology

ASH Home
Research
Education
Advocacy
Meetings
Publications
ASH Store

Copyright 2024 by American Society of Hematology

Cookie Settings
Privacy Policy
Cookie Policy
Terms of Use
Contact Us

This Feature Is Available To Subscribers Only

Sign In or Create an Account

Advertisement intended for health care professionals